Efficacy of repeated cycles of combination therapy for the eradication of infecting organisms in chronic bacterial prostatitis

详细信息    查看全文

• 作者：Vittorio Magri ; Alberto Trinchieri ; Giacomo Pozzi ; Antonella Restelli ; Maria Cristina Garlaschi ; Erminio Torresani ; Pasquale Zirpoli ; Emanuela Marras ; Gianpaolo Perletti
• 关键词：Chronic bacterial prostatitis ; Azythromicin ; Ciprofloxacin ; Alfuzosin ; Serenoa repens ; NIH-CPSI
• 刊名：International Journal of Antimicrobial Agents
• 出版年：2007
• 出版时间：May 2007
• 年：2007
• 卷：29
• 期：5
• 页码：549-556
• 全文大小：187 K

文摘

A total of 137 patients with a diagnosis of chronic bacterial prostatitis (CBP) were subjected to combination pharmacological therapy with antibacterial agents (ciprofloxacin/azithromycin), alpha-blockers (alfuzosin) and Serenoa repens extracts. Of those, 88 patients (64.2 % ) showed microbiological eradication at the completion of a 6-week cycle of therapy. Of the remaining 49 patients showing persistence of the causative organism(s) or reinfection at the end of treatment, 36 completed a second cycle of combination therapy for 6 weeks: 27 patients (75 % ) showed eradication of the causative organism, whereas in nine cases persistence or reinfection was observed. The cumulative eradication rate of the present study – calculated on a total of 137 enrolled patients – is 83.9 % .

Clinical examination showed a marked improvement of signs and symptoms linked to prostatitis. Remarkably, combination therapy could attenuate CBP symptoms prior to microbiological eradication, thus rapidly decreasing the impact of the disease on the quality of life of patients. Clinical remission was extended throughout a follow-up period of 30 months for 94 % of patients, whereas seven patients showed relapse of the disease.

In summary, our results indicate that about 20 % of patients enrolled in this study, who were refractory to a protocol of 6-week combination therapy, could be ‘rescued’ by a second cycle of treatment. Clinical follow-up data show that combination therapy could ensure extended relief from CBP symptoms, and a general improvement in quality of life.